# Extension Study of RA101495 for Patients With PNH Who Have Completed a Zilucoplan (RA101495) Clinical Study

> **NCT03225287** · PHASE2 · TERMINATED · sponsor: **Ra Pharmaceuticals, Inc.** · enrollment: 19 (actual)

## Conditions studied

- Paroxysmal Nocturnal Hemoglobinuria (PNH)

## Interventions

- **DRUG:** Zilucoplan (RA101495)

## Key facts

- **NCT ID:** NCT03225287
- **Lead sponsor:** Ra Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-07-17
- **Primary completion:** 2021-09-07
- **Final completion:** 2021-10-26
- **Target enrollment:** 19 (ACTUAL)
- **Why stopped:** After careful consideration, UCB has decided to no longer pursue PNH as a potential indication for zilucoplan.
- **Last updated:** 2023-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03225287

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03225287, "Extension Study of RA101495 for Patients With PNH Who Have Completed a Zilucoplan (RA101495) Clinical Study". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03225287. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*